Modality
siRNA
MOA
C5i
Target
AuroraA
Pathway
Ferroptosis
GIST
Development Pipeline
Preclinical
~Dec 2016
→ ~Mar 2018
Phase 1
Jun 2018
→ Jun 2029
Phase 1Current
NCT08067850
1,726 pts·GIST
2018-06→2026-05·Not yet recruiting
NCT06826865
1,231 pts·GIST
2025-03→2029-06·Recruiting
2,957 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-05-101mo awayInterim· GIST
2029-06-043.2y awayInterim· GIST
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P1
Not yet…
P1
Recruit…
Catalysts
Interim
2026-05-10 · 1mo away
GIST
Interim
2029-06-04 · 3.2y away
GIST
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08067850 | Phase 1 | GIST | Not yet recr... | 1726 | EDSS |
| NCT06826865 | Phase 1 | GIST | Recruiting | 1231 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Motarapivir | GSK | Preclinical | AuroraA | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| ARG-6988 | Argenx | Preclinical | AuroraA | |
| Rimabrutinib | Madrigal Pharma | Phase 1/2 | GPRC5D | |
| XEN-577 | Xenon Pharma | Phase 2/3 | C5 | |
| Semamavacamten | Ideaya Bio | Phase 1/2 | AuroraA | |
| Cevinaritide | Praxis Precision | Phase 3 | AuroraA | |
| SND-4562 | Syndax | NDA/BLA | AuroraA |